Targeting transcriptional regulators to regenerate midbrain dopaminergic axons in Parkinson's disease

Simple item page
dc.contributor.authorHegarty, Shane V.
dc.contributor.authorSullivan, Aideen M.
dc.contributor.authorO'Keeffe, Gerard W.
dc.contributor.funderScience Foundation Ireland
dc.contributor.funderRoyal Irish Academy
dc.contributor.funderNational University of Ireland
dc.contributor.funderIrish Research Council
dc.date.accessioned2018-02-06T13:36:27Z
dc.date.available2018-02-06T13:36:27Z
dc.date.issued2017
dc.description.abstractParkinson's disease (PD) is a chronic, age-related neurodegenerative disorder that affects 1–2% of the population over the age of 65. PD is characterised by the progressive degeneration of nigrostriatal dopaminergic (DA) neurons. This leads to disabling motor symptoms, due to the striatal DA denervation. Despite decades of research, there is still no therapy that can slow, stop or regenerate the dying midbrain DA neurons in PD. Current drug treatment regimes typically involve dopamine-replacement strategies. While these are effective in controlling the symptoms for several years, they do not attenuate the progressive neurodegeneration. There is now robust evidence that retrograde degeneration of nigrostriatal axons occurs early in PD pathogenesis, and precedes neuronal loss (Kordower et al., 2013). Therefore, a promising approach for restoring motor function in PD patients may be to develop strategies which regenerate nigrostriatal DA axons, so that they can re-establish their lost connections [Figure 1]. To address this, investigation of the potential for reactivation of the intrinsic axon growth capacity of midbrain DA neurons is needed. Information on the molecular mechanisms regulating nigrostriatal DA axonal growth and target innervation during their normal development will provide novel targets for axon regenerative therapy in PDen
dc.description.sponsorshipIrish Research Council (R15897); National University of Ireland (R16189); Royal Irish Academy (SVH/AMS/GWO'K)en
dc.description.statusPeer revieweden
dc.description.versionPublished Versionen
dc.format.mimetypeapplication/pdfen
dc.identifier.citationHegarty, S., Sullivan, A., and O'Keeffe, G. W. (2017) 'Targeting transcriptional regulators to regenerate midbrain dopaminergic axons in Parkinson's disease', Neural Regeneration Research, 12(11), pp. 1814-1815 doi: 10.4103/1673-5374.219039en
dc.identifier.doi10.4103/1673-5374.219039
dc.identifier.endpage1815
dc.identifier.issn1673-5374
dc.identifier.issued11
dc.identifier.journaltitleNeural Regeneration Researchen
dc.identifier.startpage1814
dc.identifier.urihttps://hdl.handle.net/10468/5380
dc.identifier.volume12
dc.language.isoenen
dc.publisherMedknow Publicationsen
dc.relation.projectinfo:eu-repo/grantAgreement/SFI/SFI Career Development Award/15/CDA/3498/IE/Development of GDF5 neurotrophic factor therapy for Parkinson_s disease./
dc.relation.urihttp://www.nrronline.org/article.asp?issn=1673-5374;year=2017;volume=12;issue=11;spage=1814;epage=1815;aulast=Hegarty
dc.rights© 2017, Medknow Publications. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under identical terms.en
dc.rights.urihttps://creativecommons.org/licenses/by-nc-sa/3.0/ie/
dc.subjectParkinson’s diseaseen
dc.subjectAxonsen
dc.subjectAxon regenerative therapyen
dc.subjectDopaminergic axonsen
dc.titleTargeting transcriptional regulators to regenerate midbrain dopaminergic axons in Parkinson's diseaseen
dc.typeArticle (peer-reviewed)en
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
4406.pdf
Size:
534.65 KB
Format:
Adobe Portable Document Format
Description:
Published Version
Download
Collections
Anatomy and Neuroscience - Journal Articles